Mcrae Capital Management Inc. Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mcrae Capital Management Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 10.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,391 shares of the company’s stock after buying an additional 1,993 shares during the quarter. Johnson & Johnson makes up about 1.1% of Mcrae Capital Management Inc.’s portfolio, making the stock its 29th biggest position. Mcrae Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,185,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Citizens National Bank Trust Department boosted its position in Johnson & Johnson by 3.4% during the 3rd quarter. Citizens National Bank Trust Department now owns 68,122 shares of the company’s stock valued at $10,142,000 after acquiring an additional 2,250 shares in the last quarter. Boyar Asset Management Inc. boosted its position in Johnson & Johnson by 1.9% during the 3rd quarter. Boyar Asset Management Inc. now owns 22,157 shares of the company’s stock valued at $3,299,000 after acquiring an additional 414 shares in the last quarter. Hengehold Capital Management LLC boosted its position in Johnson & Johnson by 4.5% during the 3rd quarter. Hengehold Capital Management LLC now owns 14,037 shares of the company’s stock valued at $2,090,000 after acquiring an additional 599 shares in the last quarter. Wade G W & Inc. boosted its position in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Wade G W & Inc. now owns 156,423 shares of the company’s stock worth $23,288,000 after purchasing an additional 1,006 shares in the last quarter. Finally, Zeke Capital Advisors LLC boosted its position in shares of Johnson & Johnson by 6.5% in the 3rd quarter. Zeke Capital Advisors LLC now owns 3,148 shares of the company’s stock worth $469,000 after purchasing an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 67.44% of the company’s stock.

Shares of Johnson & Johnson stock opened at $146.36 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The business has a 50-day moving average price of $145.51 and a 200 day moving average price of $146.57. The firm has a market cap of $385.30 billion, a PE ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. During the same quarter in the previous year, the business earned $2.12 EPS. Johnson & Johnson’s revenue for the quarter was up 1.7% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 7.99 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s payout ratio is 46.54%.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.27% of the company’s stock.

JNJ has been the subject of a number of recent analyst reports. Credit Suisse Group raised their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Cantor Fitzgerald raised their target price on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $164.93.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Insider Trading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.